

ESC Declaration of Interests Report

2025 ESC Guidelines for the management of myocarditis and pericarditis

All experts contributing to the development of ESC Guidelines must adhere to the *ESC Declaration and Management of Conflicts of Interest Policy*, ensuring transparency and ethical integrity throughout the Guidelines development process.

In accordance with this policy, they are required to submit a yearly Declaration of Interests (DOI). Each DOI undergoes a review based on established policy criteria, as defined in the policy's annex 3, enabling continuous assessment and management of potential conflicts of interest.

For this Guideline, the DOI assessment process began in 2023, evaluating declarations from 2022, and continued in 2024 and 2025—each year including an assessment of interests declared in the preceding calendar year.

Accordingly, for Task Force members, this report includes information declared for years 2022 through 2024. For reviewers, this report includes information declared for years 2023 and 2024.

Experts developing this Guideline have committed to upholding compliance with the policy criteria through 2025, including adherence to a 10,000 EUR threshold for personal payments.

The latest version of the policy and its annexes can be accessed on the ESC website at www.escardio.org/DOI.

2025 Guidelines for the management of myocarditis and pericarditis - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Adler Yehuda	2022	Nothing to be declared
	2023	Nothing to be declared
	2024	Nothing to be declared
Brucato Antonio	2022	Research funding from healthcare industry under your direct/personal responsibility (to department or institution). SOBI : to analyse inflammasome activation in pericardial fluid in acute pericarditis and chronic pericardial effusions, chief investigator
	2023	Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity CARIPLO Cassa di Risparmio Province Lombarde Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. SOBI : to analyse inflammasome activation in pericardial fluid in acute pericarditis and chronic pericardial effusions, chief investigator
	2024	Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity CARIPLO Cassa di Risparmio Province Lombarde Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. SOBI : to analyse inflammasome activation in pericardial fluid in acute pericarditis and chronic pericardial effusions, chief investigator Kiniksa : unrestricted research grant to support a data manager, chief investigator
Christian Vanessa	2022	Nothing to be declared
	2023	Nothing to be declared
	2024	Nothing to be declared
Collini Valentino	2022	Nothing to be declared
	2023	Nothing to be declared
	2024	Nothing to be declared
Ferreira Vanessa	2022	Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. Society for Cardiovascular Magnetic Resonance (SCMR) Vice Secretary Treasurer (SCMR is a charity)

2025 Guidelines for the management of myocarditis and pericarditis - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Ferreira Vanessa	<p>2023</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Siemens Healthcare : Cardiac Magnetic Resonance (CMR)</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. General Electric Healthcare : Cardiovascular magnetic resonance (CMR) parametric mapping research, Joint investigator</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Society for Cardiovascular Magnetic Resonance (SCMR) Vice Secretary Treasurer 2023-2024 (SCMR is a charity) Society for Cardiovascular Magnetic Resonance (SCMR) Secretary Treasurer 2024-2025 (SCMR is a charity)</p>
	<p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. General Electric Healthcare : Cardiac Magnetic Resonance (CMR) JCA Seminars : Cardiac Magnetic Resonance (CMR)</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. General Electric Healthcare : Cardiovascular magnetic resonance (CMR) parametric mapping research, Joint investigator</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Society for Cardiovascular Magnetic Resonance (SCMR) Secretary Treasurer Jan 2024- Jan 2025 (SCMR is a charity) Associate Editor – Frontiers of Cardiovascular Medicine. Section: Precision Cardiology Associate Editor - Frontiers of Cardiovascular Medicine – AI in CV Imaging</p>

2025 Guidelines for the management of myocarditis and pericarditis - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Gandjbakhch Estelle	2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boston Scientific : Device Therapy Medtronic : Device Therapy Biotronik : Device Therapy Microport : Device Therapy Abbott : Interventional Cardiology Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Boston Scientific : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator Medtronic : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator Microport : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator
	2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boston Scientific : Device Therapy Medtronic : Device Therapy Biotronik : Device Therapy Microport : Device Therapy Abbott : Interventional Cardiology Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Biotronik : research grant for academic research on inherited arrhythmia and catheter ablation, investigator Boston Scientific : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator Medtronic : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator Microport : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator

2025 Guidelines for the management of myocarditis and pericarditis - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Gandjbakhch Estelle	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</p> <p>Boston Scientific : Device Therapy</p> <p>Medtronic : Device Therapy</p> <p>Biotronik : Device Therapy</p> <p>Zoll Medical : Device Therapy</p> <p>Microport : Device Therapy</p> <p>Abbott : Interventional Cardiology</p> <p>Tenaya : Myocardial Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</p> <p>Biotronik : research grant for academic research on inherited arrhythmia and catheter ablation, investigator</p> <p>Boston Scientific : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator</p> <p>Medtronic : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator</p> <p>Microport : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator</p>
Groeschel Jan Wolfgang	2022	Nothing to be declared
	2023	Nothing to be declared
	2024	Nothing to be declared
Heidecker Bettina	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Pfizer, Bayer, Sanofi-Aventis, Novartis : Clinical Skills, Chronic Heart Failure, Acute Heart Failure, Myocardial Disease, Pericardial Disease</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <p>Pfizer : Analysis of biomarkers in blood of patients with amyloidosis; assess risk for adverse cardiovascular events, Principal investigator</p>

2025 Guidelines for the management of myocarditis and pericarditis - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Heidecker Bettina	2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Pfizer Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer, Bayer, Sanofi-Aventis, Novartis, Astra Zeneca : Clinical Skills, Chronic Heart Failure, Acute Heart Failure, Myocardial Disease, Pericardial Disease Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Pfizer : Analysis of biomarkers in blood of patients with amyloidosis; assess risk for adverse cardiovascular events, Principal investigator
	2024 Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Pfizer Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer, Bayer, Sanofi-Aventis, Novartis, Astra Zeneca : Clinical Skills , Chronic Heart Failure , Acute Heart Failure , Myocardial Disease , Pericardial Disease Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Pfizer : Analysis of biomarkers in blood of patients with amyloidosis; assess risk for adverse cardiovascular events, Principal investigator
Imazio Massimo	2022 Nothing to be declared
	2023 Nothing to be declared
	2024 Nothing to be declared

2025 Guidelines for the management of myocarditis and pericarditis - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Kerneis Mathieu	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Kiniksa : Myocardial Disease</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Eligo : Myocardial Disease</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Sanofi Aventis : Acute Cardiac Care Terumo Inc : Acute Coronary Syndromes</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). CardioL Therapeutics : National Coordinator of a Randomized controlled trial in Acute myocarditis evaluating the effect of CBD , national coordinator</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I am member of the ACTION Study Group, an academic research organization based in Paris, that federates professionals, patients and public with the aim to promote knowledge, information, training, prevention and research on cardiovascular diseases. I am UNPAID for this role.</p>

2025 Guidelines for the management of myocarditis and pericarditis - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Kerneis Mathieu	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity ACTION Coeur Federation francaise de cardiologie</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Kiniksa : Myocardial Disease</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Eligo : Myocardial Disease</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Terumo Inc : Acute Coronary Syndromes</p> <p>Receipt of royalties for intellectual property. Assistance publique Hopitaux de Paris : Myocardial Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. CardioL Therapeutics : National Coordinator of a Randomized controlled trial in Acute myocarditis evaluating the effect of CBD , national coordinator</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). I am member of the ACTION Study Group, an academic research organization based in Paris, that federates professionals, patients and public with the aim to promote knowledge, information, training, prevention and research on cardiovascular diseases. I am UNPAID for this role.</p>

2025 Guidelines for the management of myocarditis and pericarditis - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Kerneis Mathieu	<p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity ACTION Coeur Federation francaise de cardiologie</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Kiniksa : Myocardial Disease</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Sanofi Aventis : Acute Coronary Syndromes</p> <p>Receipt of royalties for intellectual property. Assistance publique Hopitaux de Paris : Myocardial Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. CardioL Therapeutics : National Coordinator of a Randomized controlled trial in Acute myocarditis evaluating the effect of CBD , national coordinator</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). I am member of the ACTION Study Group, an academic research organization based in Paris, that federates professionals, patients and public with the aim to promote knowledge, information, training, prevention and research on cardiovascular diseases. I am UNPAID for this role.</p>
Klein Allan	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Kiniksa : Pericardial Disease</p> <p>Receipt of royalties for intellectual property. Elsevier : Echocardiography Wolters Kluwer : Echocardiography</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Kiniksa : Randomized trial, Principle investigator</p>

2025 Guidelines for the management of myocarditis and pericarditis - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Klein Allan	2023	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Kiniksa : Pericardial Disease</p> <p>Receipt of royalties for intellectual property. Elsevier : Echocardiography Wolters Kluwer : Echocardiography</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Kiniksa : role of steroids in recurrent pericarditis, Principle investigator</p>
	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Kiniksa : Pericardial Disease</p> <p>Receipt of royalties for intellectual property. Elsevier : Echocardiography Wolters Kluwer : Echocardiography</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Kiniksa : role of steroids in recurrent pericarditis, Principle investigator</p>
Klingel Karin	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Myocardial Disease Alnylam : Myocardial Disease</p>
	2023	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : Myocardial Disease Alnylam : Myocardial Disease</p>
	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : Myocardial Disease</p>

2025 Guidelines for the management of myocarditis and pericarditis - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Lazaros George	2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Roche Diagnostics : Acute Coronary Syndromes Bayer : Pharmacology and Pharmacotherapy Menarini : Pharmacology and Pharmacotherapy
	2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : Chronic Heart Failure Menarini : Pharmacology and Pharmacotherapy
	2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Chronic Heart Failure Pfizer : Chronic Heart Failure Menarini : Pharmacology and Pharmacotherapy Monte Rosa : Pharmacology and Pharmacotherapy
Lorusso Roberto	2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abiomed : Acute Heart Failure XENIOS : Acute Heart Failure Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Acute Heart Failure Llvanova : Acute Heart Failure Eurosets : Acute Heart Failure Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Llvanova : Research grant about improvement of extracorporeal circulation management, Principal Investigator Medtronic : Research grant on the circulatory support for acute right ventricular failure in animal model, Principal Investigator

2025 Guidelines for the management of myocarditis and pericarditis - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Lorusso Roberto	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abiomed : Acute Heart Failure XENIOS : Device Therapy, Acute Heart Failure</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Medtronic : Device Therapy, Acute Heart Failure, Cardiovascular Surgery Llvanova : Device Therapy, Acute Heart Failure, Cardiovascular Surgery GETINGE : Device Therapy, Acute Heart Failure, Cardiovascular Surgery Eurosets : Device Therapy, Acute Heart Failure, Cardiovascular Surgery</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Medtronic : Research grant on animal experiments for mechanical circulatory support in acute heart failure, Chief investigator Llvanova : Research grant to develop device and system related to extracorporeal circulation, Chief investigator</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editor-in-Chief of the EACTS MultiMedia Manual on Cardio-Thoracic Surgery (Digital and Video Tutorials and Case Reports) Associate Editor of Artificial Organs Associate Editor of the European Heart Journal Case Report</p>

2025 Guidelines for the management of myocarditis and pericarditis - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Lorusso Roberto	<p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abiomed : Acute Heart Failure, Cardiovascular Surgery</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Medtronic : Acute Heart Failure, Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure, Cardiovascular Surgery Llvanova : Acute Heart Failure, Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure, Cardiovascular Surgery Eurosets : Acute Heart Failure, Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure, Cardiovascular Surgery XENIOS : Acute Heart Failure, Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure, Cardiovascular Surgery</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Llvanova : Development and tests of a new device for extracorporeal circulation (cardiopulmonary bypass and ECMO), Chief Investigator Medtronic : Research grant to support animal experiment on right ventricular support for acute right ventricular failure and vent-venous ECMO configurations, Chief Investigator</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editor-in-Chief of the Multi-Media Manual of Cardio-Thoracic Surgery (by European Association of Cardio-Thoracic Surgery)</p>
Nesukay Elena	<p>2022 Nothing to be declared</p> <p>2023 Nothing to be declared</p> <p>2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Congenital Heart Disease and Paediatric Cardiology</p>
Rahimi Kazem	<p>2022 Receipt of royalties for intellectual property. Sensyne Health : e-Cardiology/Digital Health</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Novo-Nordisk : Research Grant, University Of Oxford, Co-Principal Investigator</p>

2025 Guidelines for the management of myocarditis and pericarditis - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Rahimi Kazem	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Hypertension</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Medtronic Renal Denervation : Hypertension</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Novo-Nordisk : Research Grant, University Of Oxford, Co-Principal Investigator</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editor-in-Chief, BMJ Heart</p>
	<p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Medtronic : Hypertension</p>

2025 Guidelines for the management of myocarditis and pericarditis - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Ristic Arsen	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Actavis : Chronic Heart Failure Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Pfizer : Myocardial Disease Takeda Pharmaceuticals : Myocardial Disease Janssen-Cilag : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure Merck Sharp & Dohme : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure Hemofarm Stada : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Janssen-Cilag : Pulmonary hypertension clinical trial, Principal investigator Pfizer : Pulmonary hypertension clinical trial, Principal investigator United Therapeutics : Pulmonary hypertension clinical trial, Principal investigator</p> <p>Research funding (personal) from healthcare industry. Boehringer-Ingelheim : Empagliflozin after ACS, Principal investigator Novo-Nordisk : GLP1 RA clinical trial, Principal investigator Novartis : Inclisiran clinical trial, National coordinator and PI</p>
	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Actavis : Chronic Heart Failure Novo-Nordisk : Chronic Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p>

2025 Guidelines for the management of myocarditis and pericarditis - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Ristic Arsen	<p> Pfizer : Myocardial Disease Takeda Pharmaceuticals : Myocardial Disease Genesis : Myocardial Disease Kiniksa : Pericardial Disease Janssen-Cilag : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure Merck Sharp & Dohme : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure Hemofarm Stada : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Boehringer-Ingelheim : Chronic Heart Failure Chiesi Pharma : Myocardial Disease Research funding from healthcare industry received personally by you or an entity controlled by you. Boehringer-Ingelheim Novartis Novo-Nordisk Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. ANCORA Heart : chronic heart failure, Principal investigator Janssen-Cilag : Pulmonary hypertension clinical trial, Principal investigator Pfizer : Pulmonary hypertension clinical trial, Principal investigator United Therapeutics : Pulmonary hypertension clinical trial, Principal investigator Gossamer Bio : Pulmonary hypertension, Principal investigator </p> <hr/> <p> 2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Actavis : Chronic Heart Failure </p>

2025 Guidelines for the management of myocarditis and pericarditis - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Ristic Arsen	<p>Ewopharma : Chronic Heart Failure Novo-Nordisk : Chronic Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Bayer : Chronic Heart Failure, Myocardial Disease Pfizer : Myocardial Disease Takeda Pharmaceuticals : Myocardial Disease Genesis : Myocardial Disease Providens : Myocardial Disease Kiniksa : Pericardial Disease Janssen-Cilag : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure Merck Sharp & Dohme : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure Hemofarm Stada : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure SwixxBiopharma : Risk Factors and Prevention</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Boehringer-Ingelheim : Chronic Heart Failure Chiesi Pharma : Myocardial Disease</p> <p>Research funding from healthcare industry received personally by you or an entity controlled by you. Boehringer-Ingelheim Novartis Novo-Nordisk Gossamer Bio</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. ANCORA Heart : chronic heart failure, Principal investigator Janssen-Cilag : Pulmonary hypertension clinical trial, Principal investigator Pfizer : Pulmonary hypertension clinical trial, Principal investigator United Therapeutics : Pulmonary hypertension clinical trial, Principal investigator Gossamer Bio : Pulmonary hypertension, Principal investigator</p>

2025 Guidelines for the management of myocarditis and pericarditis - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Rucinski Marcin	2022	Membership or affiliation in political or advocacy groups working in the field of cardiology. Member of Polish Cardiac Society
	2023	Membership or affiliation in political or advocacy groups working in the field of cardiology. Member of Polish Cardiac Society
	2024	Nothing to be declared
Sade L Elif	2022	Nothing to be declared
	2023	Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity My current research fundings are generated by the University of Pittsburgh
	2024	Nothing to be declared
Schaubroeck Hannah	2022	Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : Acute Heart Failure Abiomed : Acute Heart Failure, Acute Cardiac Care, Other Research funding from healthcare industry under your direct/personal responsibility (to department or institution). GETINGE : MCS national registry (BIWAC), principal investigator Membership or affiliation in political or advocacy groups working in the field of cardiology. Board member (and past president) of Belgian Interdisciplinary working group of acute cardiology (BIWAC) - daughter organisation of BSC (Belgian society of Cardiology) BSC member (Belgian society of Cardiology) ISICEM faculty 2023 (International Symposium on Intensive Care and Emergency Medicine) ESICEM member (European society of Intensive Care Medicine)

2025 Guidelines for the management of myocarditis and pericarditis - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Schaubroeck Hannah	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Belgian Interdisciplinary Working group of Acute Cardiology (BIWAC)</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Acute Heart Failure</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Abiomed : Acute Heart Failure, Research Methodology</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. GETINGE : MCS national registry (BIWAC), principal investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Board member (and past president) of Belgian Interdisciplinary working group of acute cardiology (BIWAC) - daughter organisation of BSC (Belgian society of Cardiology) BSC member (Belgian society of Cardiology) ISICEM faculty 2023 (International Symposium on Intensive Care and Emergency Medicine) ESICEM member (European society of Intensive Care Medicine)</p>
	<p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Belgian Interdisciplinary Working group of Acute Cardiology (BIWAC)</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abiomed : Acute Heart Failure</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Abiomed : Acute Heart Failure, Research Methodology</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. GETINGE : MCS national registry (BIWAC), principal investigator</p>

2025 Guidelines for the management of myocarditis and pericarditis - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Schaubroeck Hannah	2024	Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Board member (and past president) of Belgian Interdisciplinary working group of acute cardiology (BIWAC) - daughter organisation of BSC (Belgian society of Cardiology) BSC member (Belgian society of Cardiology) ESICEM member (European society of Intensive Care Medicine)
Schulz-Menger Jeanette	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Circle institute - only dedicated to education : Cardiac Magnetic Resonance (CMR)
	2023	Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Circle institute : Other Membership or affiliation in political or advocacy groups working in the field of cardiology. Society for Cardiovascular Magnetic Resonance German Society of Cardiology
	2024	Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. SCMR DGK
Semb Anne Grete	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Cardiovascular Disease in Special Populations
	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Cardiovascular Disease in Special Populations
	2024	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Risk Factors and Prevention Finnish Sociesty for Rheumatology : Risk Factors and Prevention, Cardiovascular Disease in Special Populations
Sinagra Gianfranco	2022	Nothing to be declared
	2023	Nothing to be declared
	2024	Nothing to be declared

2025 Guidelines for the management of myocarditis and pericarditis - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Thune Jens Jakob	2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Clinical Skills, Chronic Heart Failure, Acute Heart Failure
	2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Clinical Skills, Chronic Heart Failure, Acute Heart Failure Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Cytokinetics : Myocardial Disease Membership or affiliation in political or advocacy groups working in the field of cardiology. Member of the Danish Heart Foundation
	2024 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bristol Myers Squibb : Myocardial Disease Cytokinetics : Myocardial Disease Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Astra Zeneca : Chronic Heart Failure, Acute Heart Failure, Myocardial Disease Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Member of the Danish Heart Foundation

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Abirached Naji	2023	Nothing to be declared
	2024	Nothing to be declared
Adamo Marianna	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Edwards Lifesciences : Valvular Heart Disease Abbott Vascular : Valvular Heart Disease
	2024	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Edwards Lifesciences : Valvular Heart Disease Abbott Vascular : Valvular Heart Disease
Agladze Vaja	2023	Nothing to be declared
	2024	Nothing to be declared
Aktaa Suleman	2023	Nothing to be declared
	2024	Nothing to be declared
Ammirati Enrico	2023	Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity European Union Italian Ministry of Health Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Cytokinetics : Chronic Heart Failure Astra Zeneca : Myocardial Disease Kiniksa : Myocardial Disease Membership or affiliation in political or advocacy groups working in the field of cardiology. Member of the Advisory medical board of the Myocarditis Foundation. No profit organization. I receive no payments from this appointment.

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Ammirati Enrico	<p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity European Union Italian Ministry of Health</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Cytokinetics : Chronic Heart Failure Astra Zeneca : Myocardial Disease Kiniksa : Myocardial Disease</p>
Anderson Lisa	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Alnylam : Chronic Heart Failure</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Abbott : Chronic Heart Failure</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Pfizer : Junior fellowship grant Transthyretin Amyloid fellow = Dr Sofia Papdopoulou, Research supervisor</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Chair, British Society for Heart Failure Chair, NHS England Expert Advisory Group</p>

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Anderson Lisa	<p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Alnylam : Chronic Heart Failure</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. CPC Clinical Research : Acute Heart Failure</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Abbott : Chronic Heart Failure Roche Diagnostics : Chronic Heart Failure, Other</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Pfizer : Junior fellowship grant Transthyretin Amyloid fellow = Dr Sofia Papadopoulou, Research supervisor</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Chair, British Society for Heart Failure Chair, NHS England Expert Advisory Group</p>
Arbelo Elena	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Marató TV3</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Atrial Fibrillation (AF) Biosense Webster : Atrial Fibrillation (AF)</p> <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boston Scientific : Arrhythmias, General Bristol Myers Squibb : Myocardial Disease Medtronic : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p>

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Arbelo Elena	2024	Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Chair of the EHRA Advocacy, Quality improvement and Health Economics Committee Member of the ESC Advocacy Committee
Arbustini Eloisa	2023	Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Italian Ministry of Health
	2024	Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Italian Ministry of Health
Arefalk Gabriel	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure, Acute Heart Failure Boehringer-Ingelheim : Chronic Heart Failure, Acute Heart Failure Orion : Chronic Heart Failure, Acute Heart Failure Sanofi Aventis : Risk Factors and Prevention
	2024	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure, Acute Heart Failure Boehringer-Ingelheim : Chronic Heart Failure, Acute Heart Failure Orion : Chronic Heart Failure, Acute Heart Failure Sanofi Aventis : Risk Factors and Prevention
Bani Marjeh Mohammed Yassin	2023	Nothing to be declared
	2024	Nothing to be declared
Banushi Albana Doko	2023	Nothing to be declared
	2024	Nothing to be declared
Basso Cristina	2023	Nothing to be declared
	2024	Nothing to be declared

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Begic Alden	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Myocardial Disease
	2024	Nothing to be declared
Berthelot Emmanuelle	2023	Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity SFC cardio Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Bayer : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure
	2024	Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity SFC cardio Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Bayer : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure
Bijvoet Geertruida Petronella	2023	Nothing to be declared
	2024	Nothing to be declared
Bobbio Emanuele	2023	Nothing to be declared
	2024	Nothing to be declared
Boriani Giuseppe	2023	Nothing to be declared

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Borioni Giuseppe	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bristol Myers Squibb : Arrhythmias, General Daiichi Sankyo : Atrial Fibrillation (AF) Boston Scientific : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Member of the Editorial Board of Acta Cardiologica and European Journal of Internal Medicine</p>
Brida Margarita	2023	Nothing to be declared
	2024	Nothing to be declared
Byrne Robert	2023	<p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Biosensors : Clinical trial activity, Principal investigator Abbott Vascular : Research/educational grant to institution of employment to support fellowship programme, Clinical director Boston Scientific : Research/educational grant to institution of employment to support fellowship programme, Principal investigator Translumina : Research/educational grant to institution of employment to support research nurse for patient outcomes, Principal investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Member of Irish Heart Attack Audit Governance Committee Member Health Products Regulatory Authority (HPRA; Irish Competent Authority) Advisory Committee on Medical Devices</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Deputy Editor at EuroIntervention Guest Editor at Circulation</p>

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Byrne Robert	<p>2024</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Biosensors : Clinical trial activity, Principal investigator Boston Scientific : Research grant to institution of employment to support a clinical trial, Principal investigator Abbott Vascular : Research/educational grant to institution of employment to support fellowship programme, Clinical director Translumina : Research/educational grant to institution of employment to support research nurse for patient outcomes, Clinical director</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Member of Irish Heart Attack Audit Governance Committee Member Health Products Regulatory Authority (HPRA; Irish Competent Authority) Advisory Committee on Medical Devices</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Deputy Editor at EuroIntervention Guest Editor at Circulation</p>
Bytyci Ibadete	<p>2023</p> <p>Nothing to be declared</p>
	<p>2024</p> <p>Nothing to be declared</p>
Caforio Alida L P	<p>2023</p> <p>Nothing to be declared</p>
	<p>2024</p> <p>Nothing to be declared</p>
Cardim Nuno	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Cytokinetics : Myocardial Disease Bristol Myers Squibb-MYOKARDIA : Myocardial Disease Ferrer Internacional : Pharmacology and Pharmacotherapy</p>
	<p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Cytokinetics : Myocardial Disease Bristol Myers Squibb-MYOKARDIA : Myocardial Disease Ferrer Internacional : Pharmacology and Pharmacotherapy</p>
Cerne Cercek Andreja	<p>2023</p> <p>Nothing to be declared</p>

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Cerne Cercek Andreja	2024	Nothing to be declared
Cherniuk Sergii	2023	Nothing to be declared
	2024	Nothing to be declared
Chettibi Mohamed	2023	Nothing to be declared
	2024	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) , Risk Factors and Prevention
Codreanu Andrei	2023	Nothing to be declared
	2024	Nothing to be declared
Dan Gheorghe Andrei	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Atrial Fibrillation (AF) Berlin Chemie AG : Atrial Fibrillation (AF) Boehringer-Ingelheim : Atrial Fibrillation (AF), Chronic Heart Failure Krka Pharma : Pharmacology and Pharmacotherapy Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Berlin Chemie AG : European Society of Cardiology Membership or affiliation in political or advocacy groups working in the field of cardiology. Member of the Cardiology Consultant Commission of the Health Ministry, Romania

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Dan Gheorghe Andrei	<p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Berlin Chemie AG : Atrial Fibrillation (AF) Krka Pharma : Pharmacology and Pharmacotherapy Novartis : Risk Factors and Prevention</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Berlin Chemie AG : European Society of Cardiology</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Member of the Cardiology Consultant Commission of the Health Ministry, Romania</p>
Dankova Marcela	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : Myocardial Disease</p> <p>2024</p> <p>Nothing to be declared</p>
Daskalov Ivaylo	<p>2023</p> <p>Employment (including part time) in healthcare industry during the year for which you are declaring. Military Medical Academy, Cardiology clinic : Chief of Cardiology</p> <p>2024</p> <p>Employment (including part time) in healthcare industry. Military Medical Academy, Cardiology clinic : Chief of Cardiology</p>
Dominguez Fernando	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : Myocardial Disease</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Pfizer : Myocardial Disease</p>

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Dominguez Fernando	2024	<p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity ISCIII</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : Myocardial Disease Genzyme : Myocardial Disease Alnylam : Myocardial Disease</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Pfizer : Myocardial Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Astra Zeneca : Study on endomyocardial biopsies in cardiac amyloidosis, Subinvestigator</p>
Fabris Enrico	2023	Nothing to be declared
	2024	Nothing to be declared
Felice Tiziana	2023	Nothing to be declared
	2024	<p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Pfizer - Sponsored Amyloid congress : Myocardial Disease</p>
Fredericks Suzanne	2023	Nothing to be declared
	2024	Nothing to be declared

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Geavlete Oliviana	2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Other Novartis : Other Pfizer : Other Servier : Other Vifor International : Other Boehringer Ingelheim : Other Chesi : Other
	2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Other Novartis : Other Pfizer : Other Servier : Other Vifor International : Other Boehringer Ingelheim : Other Chesi : Other
Gerull Brenda	2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Chiesi Pharma : Chronic Heart Failure, Myocardial Disease Alnylam : Myocardial Disease Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Chiesi Pharma : Myocardial Disease

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Gerull Brenda	2024	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Chiesi Pharma : Chronic Heart Failure, Myocardial Disease Alnylam : Myocardial Disease
Goland Sorel	2023	Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca, : Chronic Heart Failure, Myocardial Disease Bristol Myers Squibb : Myocardial Disease, Cardiovascular Disease in Special Populations Cardurion : Pharmacology and Pharmacotherapy Research funding from healthcare industry received personally by you or an entity controlled by you. Bristol Myers Squibb
	2024	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Chronic Heart Failure Bristol Myers Squibb : Myocardial Disease Novo-Nordisk : Pharmacology and Pharmacotherapy Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Chronic Heart Failure Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Boehringer-Ingelheim : Chronic Heart Failure
Gulati Geeta	2023	Nothing to be declared
	2024	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astellas : Other
Haaf Philip	2023	Nothing to be declared

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Haaf Philip	2024	Nothing to be declared
Hinto Ulvi	2023	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</p> <p>Bayer : Chronic Heart Failure</p> <p>Pfizer : Myocardial Disease</p> <p>Takeda Pharmaceuticals : Myocardial Disease</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</p> <p>Bayer : Chronic Heart Failure</p> <p>Pfizer : European Society of Cardiology</p> <p>Krka Pharma : Training and Education</p>
	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</p> <p>Pfizer : Myocardial Disease</p> <p>Bristol Myers Squibb : Myocardial Disease</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</p> <p>Pfizer : Chronic Heart Failure, Myocardial Disease</p> <p>Boehringer-Ingelheim : European Society of Cardiology</p> <p>Medison pharma : European Society of Cardiology</p>
Ibanez Borja	2023	<p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</p> <p>My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomía, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p>

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Ibanez Borja	2024	Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomia, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).
Ibrahim Haytham Soliman Gharib	2023	Nothing to be declared
	2024	Nothing to be declared
Ingimarsdottir Inga Jona	2023	Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Pfizer : Acute Heart Failure Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Novartis : I receive no personal payments. For my work on the Horizon trial Novartis pays a small amount into a research fund that pays medical students for registration. , Primary investigator Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Assisstant editor of Cardiology, the medical journal based in Switzerland. This is unpaid work.
	2024	Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Novartis - only flight and hotel once : Acute Heart Failure Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Novartis : I receive no personal payments. For my work on the Horizon trial Novartis pays a small amount into a research fund that pays medical students for registration. , Primary investigator Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Assisstant editor of Cardiology, the medical journal based in Switzerland. This is unpaid work.
Ioannides Marios	2023	Nothing to be declared
	2024	Nothing to be declared

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
James Stefan	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Wallenberg foundation, Swedish heart and lung foundation</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Medtronic : Valvular Heart Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Elixir : clinical trial, study chair MSD : Clinical trial, trial executive committee Amgen : Executive committee member, Executive committee member Janssen-Cilag : Executive committee member, Executive committee member Astra Zeneca : Study PI , Principal investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Swedish medical Association, Swedish cardiac society</p>
	<p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Swedish research council</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Edwards Lifesciences : Valvular Heart Disease Medtronic : Valvular Heart Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Amgen Inc : Clinical trial, Executive committee Merck Sharp & Dohme : Clinical trial, Executive committee New Amsterdam : DSMB committee. Lipid management , DSMB committee Janssen-Cilag : Executive committee, Executive committee</p>

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
James Stefan	2024	Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Board member of the Swedish research council
Joyce Emer	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : Other Johnson & Johnson : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Astra Zeneca : Chronic Heart Failure Membership or affiliation in political or advocacy groups working in the field of cardiology. Irish Heart Foundation - non profit/ advocacy group on behalf of Irish people with CVd or at risk of - I am Chair of Heart Failure Council - this is a voluntary position Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Associate Editor at Journal of Cardiac Failure (HFSA)
	2024	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Chronic Heart Failure FIRE-1 : Device Therapy Astra Zeneca : Myocardial Disease Pfizer : Myocardial Disease Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Bayer : European Society of Cardiology Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Women as One Mentor Mentee Award : Research & Education around Cardiac Amyloidosis , Mentor paired with Mentee, PI

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Joyce Emer	<p>2024</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Chair, Heart Failure Council of Irish Heart Foundation (National CV Health advocacy group) Assistant Secretary, Irish Cardiac Society (affiliate of ESC)</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Associate Editor, Journal of Cardiac Failure</p>
Kaminski Karol	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Novo Nordisk</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Servier : Chronic Heart Failure, Rehabilitation and Sports Cardiology Novo-Nordisk : Other Janssen-Cilag : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure MSD : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure GlaxoSmithKline : Risk Factors and Prevention</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. AOP Orphan Pharmaceuticals : Chronic Heart Failure, Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure Promed : Risk Factors and Prevention</p>

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Kaminski Karol	<p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Novo Nordisk</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Servier : Chronic Heart Failure, Hypertension Sanofi Aventis : Other Janssen-Cilag : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure Novartis : Risk Factors and Prevention GlaxoSmithKline : Risk Factors and Prevention</p>
Kamzola Ginta	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Bayer : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Astra Zeneca : Chronic Heart Failure, Acute Heart Failure Boehringer-Ingelheim : Echocardiography, Cardiac Computed Tomography (CT), Cardiac Magnetic Resonance (CMR), Chronic Heart Failure Bayer : European Society of Cardiology</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Latvian Society of Cardiology</p>

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Kamzola Ginta	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Astra Zeneca : Chronic Heart Failure, Acute Heart Failure Boehringer-Ingelheim : Echocardiography, Chronic Heart Failure Bayer : European Society of Cardiology</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Latvian Society of Cardiology</p>
Kasiakogias Alexandros	2023	Nothing to be declared
	2024	Nothing to be declared
Kevorkov Amayak	2023	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Swixx Biopharma : Atrial Fibrillation (AF), Acute Coronary Syndromes, Hypertension, Risk Factors and Prevention Serene : Atrial Fibrillation (AF), Chronic Heart Failure Nobel : Atrial Fibrillation (AF), Hypertension Grindex : Chronic Heart Failure Servier : Hypertension Arterium : Hypertension</p>

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Kevorkov Amayak	<p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Swixx Biopharma : Atrial Fibrillation (AF), Acute Coronary Syndromes, Hypertension, Risk Factors and Prevention Serene : Atrial Fibrillation (AF), Chronic Heart Failure Nobel : Atrial Fibrillation (AF), Hypertension Grindex : Chronic Heart Failure Servier : Hypertension Arterium : Hypertension</p>
Kharlamov Alexander	<p>2023</p> <p>Direct financial interest in healthcare, media, education companies, or in companies related to or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Healthcare - Clinical Skills , Echocardiography , Cardiac Computed Tomography (CT) , Cardiac Magnetic Resonance (CMR) , Nuclear Imaging , Hybrid and Fusion Imaging , Cross-Modality and Multi-Modality Imaging Topics , Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) , Interventional Cardiology , e-Cardiology/Digital Health , Public Health and Health Economics - The main business target of DHRF and personal interest is an advanced cardiovascular imaging and related research service.</p> <p>2024</p> <p>Direct financial interest in healthcare, media, education companies, or in companies related to or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Healthcare - Clinical Skills , Echocardiography , Cardiac Computed Tomography (CT) , Cardiac Magnetic Resonance (CMR) , Nuclear Imaging , Hybrid and Fusion Imaging , Cross-Modality and Multi-Modality Imaging Topics , Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) , Interventional Cardiology , e-Cardiology/Digital Health , Public Health and Health Economics - The main business target of DHRF and personal interest is an advanced cardiovascular imaging and related research service.</p>
Kilicaslan Baris	<p>2023</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Chronic Heart Failure Abbott : Device Therapy</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Medtronic : Valvular Heart Disease</p>

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Kilicaslan Baris	2023	Membership or affiliation in political or advocacy groups working in the field of cardiology. Turkish Cardiology Association Turkish Interventional Cardiology Ass. Turkish Heart Failure Working Group
	2024	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abbott : Device Therapy
Klaassen Sabine	2023	Nothing to be declared
	2024	Nothing to be declared
Kluin Jolanda	2023	Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Medela : Other Medtronic : Training and Education
	2024	Nothing to be declared
Koskinas Konstantinos	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention
	2024	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Risk Factors and Prevention Merck Sharp & Dohme : Risk Factors and Prevention Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Daiichi Sankyo : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Kuchynka Petr	2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : Myocardial Disease Bristol Myers Squibb : Myocardial Disease Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Pfizer : Myocardial Disease, Pericardial Disease Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). I am associate editor in BMC Cardiovascular Disorders.
	2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : Myocardial Disease Bristol Myers Squibb : Myocardial Disease Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Pfizer : Myocardial Disease, Pericardial Disease Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). I am associate editor in BMC Cardiovascular Disorders.
Kunadian Vijay	2023 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Acute Coronary Syndromes Novo-Nordisk : Acute Coronary Syndromes Bayer : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Associate editor Heart BMJ

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Kunadian Vijay	2024	<p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</p> <p>Novo-Nordisk : Acute Coronary Syndromes</p> <p>Amgen : Risk Factors and Prevention</p> <p>Medtronic : Valvular Heart Disease</p>
Kupari Markku	2023	Nothing to be declared
	2024	Nothing to be declared
Landmesser Ulf	2023	<p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</p> <p>German Center of Cardiovascular Research (DZHK)</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</p> <p>Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p> <p>Amgen : Risk Factors and Prevention</p> <p>Novartis : Risk Factors and Prevention</p> <p>Sanofi Aventis : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</p> <p>Abbott : EXAMINE-CAD Study, Principal Investigator</p> <p>Novartis : Support of clinical study to institution, Principal investigator</p>

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Landmesser Ulf	<p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity German Center of Cardiovascular Research (DZHK) Leducq Foundation - Network of excellence in cardiovascular research</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Menarini : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Amgen : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Abbott : Clinical Study, Principal Investigator Merck Sharp & Dohme : Clinical Study, Steering Committee Novartis : Support of clinical study to institution, Principal investigator</p>
Lip Gregory Yh	<p>2023</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Boehringer-Ingelheim : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellow., Principal Investigator Anthos : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellow., Principal Investigator</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Shares in private limited company (a legal separate entity in UK), but no salary/income/personal remuneration received.</p>

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Lip Gregory Yh	<p>2024</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : Atrial Fibrillation (AF) Bristol Myers Squibb : Atrial Fibrillation (AF)</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Daiichi Sankyo : Atrial Fibrillation (AF)</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Bristol Myers Squibb : AF ‘real world’ registry work. Academic, non promotional research work on registries , project supervision Boehringer-Ingelheim : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellows., project supervision Anthos : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellows., project supervision</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editorial roles in a number of academic journals. Shares in private limited company (a legal separate entity in UK), but no salary/income/personal remuneration received.</p>
Maisch Bernhard	<p>2023</p> <p>Direct financial interest in healthcare, media, education companies, or in companies related to or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Media - coeditor of HERZ/Cardiovascular Disease Education - Honoraria from FOMF (Forum für medizinische Fortbildung) for lectures</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Coeditor of HERZ/Cardiovascular Diseases (Springer/Nature)</p>

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Maisch Bernhard	<p>2024</p> <p>Direct financial interest in healthcare, media, education companies, or in companies related to or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Media - coeditor of HERZ/Cardiovascular Disease Education - Honoraria from FOMF (Forum für medizinische Fortbildung) for lectures</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Coeditor of HERZ/Cardiovascular Diseases (Springer/Nature)</p>
Marelli-Berg Federica	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astrazeneca : Basic Science</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Astrazeneca : Preclinical Study, chief investigator</p> <p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity British Heart Foundation NIHR</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Basic Science</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Astra Zeneca : Cardiac inflammation, principal investigator</p>
Martin Pilar	<p>2023</p> <p>Nothing to be declared</p> <p>2024</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Associate Editor of the Journal of the American College of Cardiology, JACC:CardioOncology</p>
Mcevoy John William	<p>2023</p> <p>Nothing to be declared</p> <p>2024</p> <p>Nothing to be declared</p>

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Mihaylova Borislava	2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Barts Charity, UK Bowel Research UK Cancer Research UK National Institute for Health and Care Research, UK
	2024 Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Barts Charity, UK Bowel Research UK Cancer Research UK National Institute for Health and Care Research, UK
Mindham Richard	2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. NiCE (National Institute for Health & Care Excellence) - UK Government body. Guideline development.. Commences January 2024. : Chronic Heart Failure PASSpaces. http://passpaces.co.uk/ . PASSpaces tutors young British doctors to help them pass their medical examinations. I "act" as a patient, permitting the trainee to take a patient history. : Training and Education Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. European Society of Cardiology. Payment of hotel, travel and meals to attend or speak at ESC conferences. : European Society of Cardiology

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Mindham Richard	2023 Membership or affiliation in political or advocacy groups working in the field of cardiology. I support the British charity CardiomyopathyUK, https://www.cardiomyopathy.org.uk/ . I make small financial contributions to support their activities. I support the British charity Pumping Marvellous, https://pumpingmarvellous.org/ . I make no financial contributions to the charity's activities. I am a member of the Coalition for Reducing Bureaucracy in Clinical Trials, https://bureaucracyincts.eu/ . The Coalition is a collection of researchers, clinicians and patients which advocates for the reduction of bureaucracy in clinical trials, chiefly in the EU. I have no financial interest in the Coalition. Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). I have savings and pensions held in shares. The shares are managed by a financial adviser; I do not control the purchase & sale of shares and I do not know whether any shares are in medical companies.
	2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. National Institute for Health and Clinical Excellence : Chronic Heart Failure National Institute for Prevention and Cardiovascular Health (NIPC), Ireland : Rehabilitation and Sports Cardiology, Training and Education PASSpaces : Training and Education Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Cardiomyopathy UK, a British charity, registered with the government. I support the charity with donations. Heart Failure Warriors, a British charity, registered with the government. I have transferred all of the fees from NIPC (please see 2A) to HF Warriors. Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Patient member of advisory board to two Horizon-funded programmes: RAPHAEL (investigating HF palliation) and More-EUROPA (investigating Real World Data in healthcare). I receive no payments from these programmes. Patient member of UK Digital, a UK study researching patients' expectations from digital technology. I receive no payment from UK Digital. I attended the kick-off event where my train fare, hotel bill and dinner were paid for by the study.
Mirrakhimov Erkin	2023 Nothing to be declared
	2024 Nothing to be declared
Mitevaska Irena	2023 Nothing to be declared
	2024 Nothing to be declared
Mizariene Vaida	2023 Nothing to be declared

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Mizariene Vaida	2024	Nothing to be declared
Moelgaard Inge	2023	Nothing to be declared
	2024	Nothing to be declared
Mohiddin Saidi	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. American Society of Echocardiography : Myocardial Disease
	2024	Nothing to be declared
Mukarov Murat	2023	Nothing to be declared
	2024	Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Ministry of education and science of Republic of Kazakhstan Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Patient organisation
Musayev Ogtay	2023	Nothing to be declared
	2024	Nothing to be declared
Nielsen Jens Cosedis	2023	Nothing to be declared
	2024	Nothing to be declared
Paelinck Bernard P	2023	Nothing to be declared
	2024	Nothing to be declared

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Palecek Tomas	2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Czech Society of Cardiology Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Chronic Heart Failure Pfizer : Myocardial Disease Novo-Nordisk : Myocardial Disease Alnylam : Myocardial Disease Ionis : Myocardial Disease Eidos Therapeutics : Myocardial Disease Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Pfizer : Myocardial Disease
	2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Chronic Heart Failure Pfizer : Myocardial Disease Bristol Myers Squibb : Myocardial Disease
Pasquet Agnes A	2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Hypertension Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Hypertension Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Philips : echography, contribution and support

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Pasquet Agnes A	<p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Hypertension</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Hypertension</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Philips : echography, contribution and support</p>
Peretto Giovanni	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abbott : Arrhythmias, General</p> <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abbott : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p>
Pilichou Kalliopi	<p>2023</p> <p>Nothing to be declared</p> <p>2024</p> <p>Nothing to be declared</p>
Piriou Nicolas	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : Myocardial Disease Bristol Myers Squibb : Myocardial Disease Alnylam : Myocardial Disease</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Pfizer : Myocardial Disease</p>

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Piriou Nicolas	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : Myocardial Disease Bristol Myers Squibb : Myocardial Disease Alnylam : Myocardial Disease</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Pfizer : Myocardial Disease Alnylam : Myocardial Disease</p>
Prescott Eva	2023	Nothing to be declared
	2024	Nothing to be declared
Rakisheva Amina	2023	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure Roche Diagnostics : Chronic Heart Failure</p>
	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure</p>
Ravnstad Haavard	2023	Nothing to be declared
	2024	<p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Nordic InfuCare : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure</p>

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Rocca Bianca	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Cancer UK</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Aboca, SRL : Other</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editorial Board of: Assistant Editor Diabetes and Vascular Disease Research Advisory Board: Pharmadvances. Associate Editor: Cardiovascular Drugs and Therapy, Clinical Pharmacology Editorial Board: Bleeding, Thrombosis, and Vascular Biology Associate Editor. Frontiers in Drug Safety and Regulation Section on Cardiovascular Drug Safety Associate Editor for European Cardiology Review Editorial Board European Journal of Preventive Cardiology Editorial Board Journal of Thrombosis and Thrombolysis Editorial Board International Journal of Cardiology</p>
	<p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Cancer UK</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer AG : Pharmacology and Pharmacotherapy</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Bios Therapy : Substance Based medical devices in obesity, site investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. ISTH, Italian Society of Thrombosis and Haemostasis (SISET), italian society of Pharmacology (SIF), Mediterranean League against Thrombosis</p>
Rossello Francisco Javier	<p>2023</p> <p>Nothing to be declared</p>
	<p>2024</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Associate editor of Heart - https://heart.bmj.com/pages/editorial-board Associate Statistical Editor of Circulation: Cardiovascular Quality and Outcomes - https://www.ahajournals.org/circoutcomes/editorial-board</p>

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Rossing Kasper	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Abbott : Device Therapy, Chronic Heart Failure, Acute Heart Failure
	2024	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abbott : Chronic Heart Failure Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Abbott : Chronic Heart Failure Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Board member of the Danish Heart Foundation
Sannino Anna	2023	Nothing to be declared
	2024	Nothing to be declared
Seidel Franziska	2023	Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Berliner Sparkassenstiftung Medizin Deutsche Herzstiftung kinderherzen e.V. Paul-Ehrlich Institute / BMG Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). I am part of the leading study team of the multicentre registry for suspected myocarditis in children and adolescents "MYKKE".

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Seidel Franziska	<p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Berliner Sparkassenstiftung Medizin BMG Deutsche Herzstiftung kinderherzen e.V.</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. SOBI : Myocardial Disease</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). I am part of the leading study team of the multicentre registry for suspected myocarditis in children and adolescents "MYKKE".</p>
Sisakian Hamayak	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Yerevan State Medical University</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Ferrer Internacional : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Servier : Hypertension</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Servier : Hypertension trial, principal investigator</p> <hr/> <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Berlin Chemie/ Menarini : Hypertension</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Krka Pharma : Hypertension</p>

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Skoric Bosko	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</p> <p>Salveo : Acute Coronary Syndromes</p> <p>Berlin Chemie AG : Atrial Fibrillation (AF)</p> <p>Viartis : Chronic Heart Failure</p> <p>Boehringer-Ingelheim : Chronic Heart Failure, Acute Heart Failure</p> <p>Teva Pharmaceutical Industries : Chronic Heart Failure, Acute Heart Failure</p> <p>Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p> <p>Takeda Pharmaceuticals : Other</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</p> <p>Teva Pharmaceutical Industries : Chronic Heart Failure, Acute Heart Failure, Other</p> <p>Medis Adria : Other</p>

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Skoric Bosko	<p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Salveo : Acute Coronary Syndromes Berlin Chemie AG : Atrial Fibrillation (AF) Menarini : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure, Acute Heart Failure Teva Pharmaceutical Industries : Chronic Heart Failure, Acute Heart Failure Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Takeda Pharmaceuticals : Other</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Atrial Fibrillation (AF) Astra Zeneca : Chronic Heart Failure Teva Pharmaceutical Industries : Chronic Heart Failure, Acute Heart Failure, Other Astellas : Other Zentiva : Other Medis Adria : Other</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Boehringer-Ingelheim : Atrial Fibrillation (AF)</p> <p>Research funding from healthcare industry received personally by you or an entity controlled by you. Medis Adria</p>
Smer Aiman	<p>2023 Nothing to be declared</p> <p>2024 Nothing to be declared</p>
Soufiani Aida	<p>2023 Nothing to be declared</p> <p>2024 Nothing to be declared</p>

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Tanner Felix C	2023	<p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Swiss Heart Foundation</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Philips : Echocardiography</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Secretary, UEMS Cardiac Section Board, Swiss Institute for Medical Education Board, Swiss Heart Foundation Editorial Board, International Journal of Cardiology Editorial Board, Journal of Clinical Medicine Editorial Board, Swiss Medical Weekly Editorial Board, Cardiovascular Medicine</p>
	2024	<p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Swiss Heart Foundation</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Secretary, UEMS Cardiac Section Board, Swiss Institute for Medical Education Board, Swiss Heart Foundation Editorial Board, International Journal of Cardiology Editorial Board, Journal of Clinical Medicine Editorial Board, Swiss Medical Weekly</p>
Tomkowski Witold Zbyszek	2023	Nothing to be declared
	2024	Nothing to be declared
Troiani Emidio	2023	Nothing to be declared
	2024	Nothing to be declared
Vaartjes Ilonca	2023	Nothing to be declared
	2024	Nothing to be declared

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Vago Hajnalka	2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Cardiac Magnetic Resonance (CMR) Siemens Healthcare : Cardiac Magnetic Resonance (CMR) Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Siemens Healthcare : cooperation in the field of research of artificial intelligence prototypes for computer-assisted workflow automations, advanced reconstruction techniques and automated postprocessi, principal investigator
	2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Cardiac Magnetic Resonance (CMR) Siemens Healthcare : Cardiac Magnetic Resonance (CMR) Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Siemens Healthcare : cooperation in the field of research of artificial intelligence prototypes for computer-assisted workflow automations, advanced reconstruction techniques and automated postprocessi, principal investigator
Van Linthout Sophie	2023 Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Guest Editor of CIRCULATION Heart Failure since November 2022
	2024 Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Guest Editor of CIRCULATION Heart Failure since November 2022
Vataman Eleonora	2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Republic of Moldova State program Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Egis Pharma : Other

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Vataman Eleonora	<p>2024 Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Republic of Moldova State program</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Egis Pharma : Chronic Heart Failure</p>
Vrints Christiaan J M	<p>2023 Nothing to be declared</p> <p>2024 Nothing to be declared</p>
Wojnicz Romuald	<p>2023 Nothing to be declared</p> <p>2024 Nothing to be declared</p>
Zdravkovic Marija	<p>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Galenika : Atrial Fibrillation (AF) Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Siemens Healthcare : Cardiac Magnetic Resonance (CMR)</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Member of the National Assembly, Republic of Serbia. Member of the Presidency of the SNS political party</p>

2025 Guidelines for the management of myocarditis and pericarditis - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Zdravkovic Marija	<p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Faculty of Medicine, University of Belgrade Ministry of Science Republic of Serbia</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Stada Hemofarm : Acute Coronary Syndromes Galenika : Atrial Fibrillation (AF) Siemens Healthcare : Cardiac Magnetic Resonance (CMR) Astra Zeneca : Chronic Heart Failure Medtronic : Chronic Heart Failure Novartis : Chronic Heart Failure Novo-Nordisk : Chronic Heart Failure</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Siemens Healthcare : Cardiac Magnetic Resonance (CMR)</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Member of the National Assembly, Republic of Serbia. Member of the Presidency of the SNS political party</p>
Zeppenfeld Katja	<p>2023</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Biosense Webster : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Biosense Webster : Investigator initiated research, ventricular arrhythmias, PI</p> <hr/> <p>2024</p> <p>Nothing to be declared</p>

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Adamo Marianna	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Edwards Lifesciences : Valvular Heart Disease Abbott Vascular : Valvular Heart Disease
	2024	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Edwards Lifesciences : Valvular Heart Disease Abbott Vascular : Valvular Heart Disease
Aktaa Suleman	2023	Nothing to be declared
	2024	Nothing to be declared
Asselbergs Folkert	2023	Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity EU Horizon The Dutch Research Council (NWO) The Netherlands Organisation for Health Research and Development (ZonMw) Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Novartis : Implementation of common data model for heart failure care pathway , principal investigator Astra Zeneca : Nudging trial to improve guideline adherence in heart failure, principal investigator
	2024	Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Novartis : Data standardisation quality registry, principal investigator Astra Zeneca : Nudging trial to improve guideline adherence, principal investigator
Baigent Colin	2023	Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity UK Medical Research Council Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Boehringer-Ingelheim : Funding provided for the coordination of the EMPA-KIDNEY trial, Chair of Steering Committee

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Baigent Colin	<p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity UK Medical Research Council</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Boehringer-Ingelheim : Funding provided for the coordination of the EMPA-KIDNEY and EASI-KIDNEY trials, Chair of Steering Committee</p>
Borger Michael A	<p>2023</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Artivion (formerly CryoLife) : Diseases of the Aorta Abbott : Valvular Heart Disease Edwards Lifesciences : Valvular Heart Disease Medtronic : Valvular Heart Disease</p> <p>2024</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Artivion (formerly CryoLife) : Diseases of the Aorta Abbott : Valvular Heart Disease Edwards Lifesciences : Valvular Heart Disease Medtronic : Valvular Heart Disease</p>
Boriani Giuseppe	<p>2023</p> <p>Nothing to be declared</p> <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bristol Myers Squibb : Arrhythmias, General Daiichi Sankyo : Atrial Fibrillation (AF) Boston Scientific : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p>

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Boriani Giuseppe	2024	Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Member of the Editorial Board of Acta Cardiologica and European Journal of Internal Medicine
Brida Margarita	2023	Nothing to be declared
	2024	Nothing to be declared
Byrne Robert	2023	Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Biosensors : Clinical trial activity, Principal investigator Abbott Vascular : Research/educational grant to institution of employment to support fellowship programme, Clinical director Boston Scientific : Research/educational grant to institution of employment to support fellowship programme, Principal investigator Translumina : Research/educational grant to institution of employment to support research nurse for patient outcomes, Principal investigator Membership or affiliation in political or advocacy groups working in the field of cardiology. Member of Irish Heart Attack Audit Governance Committee Member Health Products Regulatory Authority (HPRA; Irish Competent Authority) Advisory Committee on Medical Devices Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Deputy Editor at EuroIntervention Guest Editor at Circulation
	2024	Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Biosensors : Clinical trial activity, Principal investigator Boston Scientific : Research grant to institution of employment to support a clinical trial, Principal investigator Abbott Vascular : Research/educational grant to institution of employment to support fellowship programme, Clinical director Translumina : Research/educational grant to institution of employment to support research nurse for patient outcomes, Clinical director

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Byrne Robert	<p>2024</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Member of Irish Heart Attack Audit Governance Committee Member Health Products Regulatory Authority (HPRA; Irish Competent Authority) Advisory Committee on Medical Devices</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Deputy Editor at EuroIntervention Guest Editor at Circulation</p>
Gandjbakhch Estelle	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boston Scientific : Device Therapy Medtronic : Device Therapy Biotronik : Device Therapy Microport : Device Therapy Abbott : Interventional Cardiology</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Biotronik : research grant for academic research on inherited arrhythmia and catheter ablation, investigator Boston Scientific : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator Medtronic : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator Microport : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator</p>

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Gandjbakhch Estelle	<p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boston Scientific : Device Therapy Medtronic : Device Therapy Biotronik : Device Therapy Zoll Medical : Device Therapy Microport : Device Therapy Abbott : Interventional Cardiology Tenaya : Myocardial Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Biotronik : research grant for academic research on inherited arrhythmia and catheter ablation, investigator Boston Scientific : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator Medtronic : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator Microport : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator</p>
Heidecker Bettina	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Pfizer</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer, Bayer, Sanofi-Aventis, Novartis, Astra Zeneca : Clinical Skills, Chronic Heart Failure, Acute Heart Failure, Myocardial Disease, Pericardial Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Pfizer : Analysis of biomarkers in blood of patients with amyloidosis; assess risk for adverse cardiovascular events, Principal investigator</p>

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Heidecker Bettina	<p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Pfizer</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer, Bayer, Sanofi-Aventis, Novartis, Astra Zeneca : Clinical Skills , Chronic Heart Failure , Acute Heart Failure , Myocardial Disease , Pericardial Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Pfizer : Analysis of biomarkers in blood of patients with amyloidosis; assess risk for adverse cardiovascular events, Principal investigator</p>
Hennemuth Anja	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity BMBF Deutsche Forschungsgemeinschaft</p> <p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity BMBF Deutsche Forschungsgemeinschaft</p>
Ibanez Borja	<p>2023</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomia, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p> <p>2024</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomia, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p>

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
James Stefan	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Wallenberg foundation, Swedish heart and lung foundation</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Medtronic : Valvular Heart Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Elixir : clinical trial, study chair MSD : Clinical trial, trial executive committee Amgen : Executive committee member, Executive committee member Janssen-Cilag : Executive committee member, Executive committee member Astra Zeneca : Study PI , Principal investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Swedish medical Association, Swedish cardiac society</p>
	<p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Swedish research council</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Edwards Lifesciences : Valvular Heart Disease Medtronic : Valvular Heart Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Amgen Inc : Clinical trial, Executive committee Merck Sharp & Dohme : Clinical trial, Executive committee New Amsterdam : DSMB committee. Lipid management , DSMB committee Janssen-Cilag : Executive committee, Executive committee</p>

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
James Stefan	2024	Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Board member of the Swedish research council
Juni Peter	2023	Nothing to be declared
	2024	Nothing to be declared
Landmesser Ulf	2023	<p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity German Center of Cardiovascular Research (DZHK)</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Amgen : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Abbott : EXAMINE-CAD Study, Principal Investigator Novartis : Support of clinical study to institution, Principal investigator</p>

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Landmesser Ulf	<p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity German Center of Cardiovascular Research (DZHK) Leducq Foundation - Network of excellence in cardiovascular research</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Menarini : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Amgen : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Abbott : Clinical Study, Principal Investigator Merck Sharp & Dohme : Clinical Study, Steering Committee Novartis : Support of clinical study to institution, Principal investigator</p>
Lip Gregory Yh	<p>2023</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Boehringer-Ingelheim : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellow., Principal Investigator Anthos : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellow., Principal Investigator</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Shares in private limited company (a legal separate entity in UK), but no salary/income/personal remuneration received.</p>

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Lip Gregory Yh	<p>2024</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : Atrial Fibrillation (AF) Bristol Myers Squibb : Atrial Fibrillation (AF)</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Daiichi Sankyo : Atrial Fibrillation (AF)</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Bristol Myers Squibb : AF 'real world' registry work. Academic, non promotional research work on registries , project supervision Boehringer-Ingelheim : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellows., project supervision Anthos : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellows., project supervision</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editorial roles in a number of academic journals. Shares in private limited company (a legal separate entity in UK), but no salary/income/personal remuneration received.</p>
Mcevoy John William	<p>2023</p> <p>Nothing to be declared</p> <p>2024</p> <p>Nothing to be declared</p>
Mihaylova Borislava	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Barts Charity, UK Bowel Research UK Cancer Research UK National Institute for Health and Care Research, UK</p>

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Mihaylova Borislava	2024	<p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</p> <p>Barts Charity, UK</p> <p>Bowel Research UK</p> <p>Cancer Research UK</p> <p>National Institute for Health and Care Research, UK</p>
Moelgaard Inge	2023	Nothing to be declared
	2024	Nothing to be declared
Neubeck Lis	2023	<p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</p> <p>Burdett Trust for Nursing</p> <p>Chief Scientists Office</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</p> <p>Sanofi Aventis : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</p> <p>Daiichi Sankyo : Atrial fibrillation screening, Principal Investigator</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</p> <p>Consultant Editor British Journal of Cardiac Nursing</p>
	2024	<p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</p> <p>Burdett Trust for Nursing</p> <p>Chief Scientists Office</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</p> <p>Consultant Editor British Journal of Cardiac Nursing</p>

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Prescott Eva	2023	Nothing to be declared
	2024	Nothing to be declared
Rocca Bianca	2023	<p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Cancer UK</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Aboca, SRL : Other</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editorial Board of: Assistant Editor Diabetes and Vascular Disease Research Advisory Board: Pharmadvances. Associate Editor: Cardiovascular Drugs and Therapy, Clinical Pharmacology Editorial Board: Bleeding, Thrombosis, and Vascular Biology Associate Editor. Frontiers in Drug Safety and Regulation Section on Cardiovascular Drug Safety Associate Editor for European Cardiology Review Editorial Board European Journal of Preventive Cardiology Editorial Board Journal of Thrombosis and Thrombolysis Editorial Board International Journal of Cardiology</p>
	2024	<p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Cancer UK</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer AG : Pharmacology and Pharmacotherapy</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Bios Therapy : Substance Based medical devices in obesity, site investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. ISTH, Italian Society of Thrombosis and Haemostasis (SISST), italian society of Pharmacology (SIF), Mediterranean League against Thrombosis</p>
Rossello Francisco Javier	2023	Nothing to be declared

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Rossello Francisco Javier	2024	<p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Associate editor of Heart - https://heart.bmj.com/pages/editorial-board Associate Statistical Editor of Circulation: Cardiovascular Quality and Outcomes - https://www.ahajournals.org/circoutcomes/editorial-board</p>
Sannino Anna	2023	Nothing to be declared
	2024	Nothing to be declared
Tanner Felix C	2023	<p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Swiss Heart Foundation</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Philips : Echocardiography</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Secretary, UEMS Cardiac Section Board, Swiss Institute for Medical Education Board, Swiss Heart Foundation Editorial Board, International Journal of Cardiology Editorial Board, Journal of Clinical Medicine Editorial Board, Swiss Medical Weekly Editorial Board, Cardiovascular Medicine</p>
	2024	<p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Swiss Heart Foundation</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Secretary, UEMS Cardiac Section Board, Swiss Institute for Medical Education Board, Swiss Heart Foundation Editorial Board, International Journal of Cardiology Editorial Board, Journal of Clinical Medicine Editorial Board, Swiss Medical Weekly</p>

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Wojakowski Wojciech	2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer Ingelheim : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure, Stroke Abbott Vascular : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Valvular Heart Disease Bristol Myers Squibb : Myocardial Disease Pfizer : Stroke
	2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer Ingelheim : Chronic Heart Failure Abbott Vascular : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Valvular Heart Disease Medtronic : Hypertension Bristol Myers Squibb : Myocardial Disease CroiValve : Valvular Heart Disease
Zeppenfeld Katja	2023 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Biosense Webster : Ventricular Arrhythmias and Sudden Cardiac Death (SCD) Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Biosense Webster : Investigator initiated research, ventricular arrhythmias, PI
	2024 Nothing to be declared